Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: A hypertensive population at high cardiovascular risk

Michael A. Weber, George L. Bakris, Björn Dahlöf, Bertram Pitt, Eric Velazquez, Jitendra Gupte, Martin Lefkowitz, Allen Hester, Victor Shi, Matthew Weir, Sverre Kjeldsen, Barry Massie, Shawna Nesbitt, Elizabeth Ofili, Kenneth Jamerson

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

ACCOMPLISH is the first trial designed to compare the effects on major fatal and non-fatal cardiovascular endpoints of two forms of antihypertensive combination therapy: benazepril plus hydrochlorothiazide and amlodipine plus benazepril in hypertensive patients at high cardiovascular risk. Enrollment for this trial is now complete and this report describes the clinical characteristics of the study cohort. Patients with hypertension and a previous history of cardiovascular events, strokes or diabetes mellitus were randomized to double-blind treatment with either of the two combination regimens. The data in this report detail the clinical history and demographic characteristics in patients immediately prior to randomization to study drugs. A total of 11,454 patients were randomized. Mean age (±SD) was 68.4±6.9 years, 60% were men, and 1360 (12%) were African American. Mean body mass index (BMI) was 31.0±6.3 kg/m2. At study entry, 46% of patients had a history of acute coronary syndromes, coronary artery bypass grafts or percutaneous coronary interventions; 13% had a history of stroke. A history of diabetes mellitus was reported in 6928 (60%) of patients. Mean blood pressure at baseline (on prior hypertension therapy) was 145.4/80.0 Hg; only 38% of patients had a BP less than 140/90mmHg. Overall, 97% of patients had received previous antihypertensive treatment (74% on at least two drugs); 53% were on oral diabetes therapy or insulin, 68% on anti-lipid therapy and 63% on anti-platelet agents. In summary, the ACCOMPLISH trial has recruited hypertensive patients at high risk of cardiovascular morbidity and mortality. It is noteworthy that the mean BMI of 31 in this cohort is clearly above the accepted diagnostic criterion of obesity and that 60% of patients are diabetic, possibly reflecting secular trends in clinical disease.

Original languageEnglish (US)
Pages (from-to)13-19
Number of pages7
JournalBlood Pressure
Volume16
Issue number1
DOIs
StatePublished - 2007

Fingerprint

Hypertension
Population
Therapeutics
Antihypertensive Agents
Diabetes Mellitus
Body Mass Index
Amlodipine
Hydrochlorothiazide
Percutaneous Coronary Intervention
Acute Coronary Syndrome
Random Allocation
Coronary Artery Bypass
Pharmaceutical Preparations
African Americans
Blood Platelets
Obesity
Stroke
Myocardial Infarction
Demography
Insulin

Keywords

  • Cardiovascular outcomes
  • Clinical trials
  • Combination therapy
  • Hypertension

ASJC Scopus subject areas

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial : A hypertensive population at high cardiovascular risk. / Weber, Michael A.; Bakris, George L.; Dahlöf, Björn; Pitt, Bertram; Velazquez, Eric; Gupte, Jitendra; Lefkowitz, Martin; Hester, Allen; Shi, Victor; Weir, Matthew; Kjeldsen, Sverre; Massie, Barry; Nesbitt, Shawna; Ofili, Elizabeth; Jamerson, Kenneth.

In: Blood Pressure, Vol. 16, No. 1, 2007, p. 13-19.

Research output: Contribution to journalArticle

Weber, MA, Bakris, GL, Dahlöf, B, Pitt, B, Velazquez, E, Gupte, J, Lefkowitz, M, Hester, A, Shi, V, Weir, M, Kjeldsen, S, Massie, B, Nesbitt, S, Ofili, E & Jamerson, K 2007, 'Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: A hypertensive population at high cardiovascular risk', Blood Pressure, vol. 16, no. 1, pp. 13-19. https://doi.org/10.1080/08037050701217643
Weber, Michael A. ; Bakris, George L. ; Dahlöf, Björn ; Pitt, Bertram ; Velazquez, Eric ; Gupte, Jitendra ; Lefkowitz, Martin ; Hester, Allen ; Shi, Victor ; Weir, Matthew ; Kjeldsen, Sverre ; Massie, Barry ; Nesbitt, Shawna ; Ofili, Elizabeth ; Jamerson, Kenneth. / Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial : A hypertensive population at high cardiovascular risk. In: Blood Pressure. 2007 ; Vol. 16, No. 1. pp. 13-19.
@article{0fec38ca9c0d4c72881b8f08a2c0b890,
title = "Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: A hypertensive population at high cardiovascular risk",
abstract = "ACCOMPLISH is the first trial designed to compare the effects on major fatal and non-fatal cardiovascular endpoints of two forms of antihypertensive combination therapy: benazepril plus hydrochlorothiazide and amlodipine plus benazepril in hypertensive patients at high cardiovascular risk. Enrollment for this trial is now complete and this report describes the clinical characteristics of the study cohort. Patients with hypertension and a previous history of cardiovascular events, strokes or diabetes mellitus were randomized to double-blind treatment with either of the two combination regimens. The data in this report detail the clinical history and demographic characteristics in patients immediately prior to randomization to study drugs. A total of 11,454 patients were randomized. Mean age (±SD) was 68.4±6.9 years, 60{\%} were men, and 1360 (12{\%}) were African American. Mean body mass index (BMI) was 31.0±6.3 kg/m2. At study entry, 46{\%} of patients had a history of acute coronary syndromes, coronary artery bypass grafts or percutaneous coronary interventions; 13{\%} had a history of stroke. A history of diabetes mellitus was reported in 6928 (60{\%}) of patients. Mean blood pressure at baseline (on prior hypertension therapy) was 145.4/80.0 Hg; only 38{\%} of patients had a BP less than 140/90mmHg. Overall, 97{\%} of patients had received previous antihypertensive treatment (74{\%} on at least two drugs); 53{\%} were on oral diabetes therapy or insulin, 68{\%} on anti-lipid therapy and 63{\%} on anti-platelet agents. In summary, the ACCOMPLISH trial has recruited hypertensive patients at high risk of cardiovascular morbidity and mortality. It is noteworthy that the mean BMI of 31 in this cohort is clearly above the accepted diagnostic criterion of obesity and that 60{\%} of patients are diabetic, possibly reflecting secular trends in clinical disease.",
keywords = "Cardiovascular outcomes, Clinical trials, Combination therapy, Hypertension",
author = "Weber, {Michael A.} and Bakris, {George L.} and Bj{\"o}rn Dahl{\"o}f and Bertram Pitt and Eric Velazquez and Jitendra Gupte and Martin Lefkowitz and Allen Hester and Victor Shi and Matthew Weir and Sverre Kjeldsen and Barry Massie and Shawna Nesbitt and Elizabeth Ofili and Kenneth Jamerson",
year = "2007",
doi = "10.1080/08037050701217643",
language = "English (US)",
volume = "16",
pages = "13--19",
journal = "Blood Pressure",
issn = "0803-7051",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial

T2 - A hypertensive population at high cardiovascular risk

AU - Weber, Michael A.

AU - Bakris, George L.

AU - Dahlöf, Björn

AU - Pitt, Bertram

AU - Velazquez, Eric

AU - Gupte, Jitendra

AU - Lefkowitz, Martin

AU - Hester, Allen

AU - Shi, Victor

AU - Weir, Matthew

AU - Kjeldsen, Sverre

AU - Massie, Barry

AU - Nesbitt, Shawna

AU - Ofili, Elizabeth

AU - Jamerson, Kenneth

PY - 2007

Y1 - 2007

N2 - ACCOMPLISH is the first trial designed to compare the effects on major fatal and non-fatal cardiovascular endpoints of two forms of antihypertensive combination therapy: benazepril plus hydrochlorothiazide and amlodipine plus benazepril in hypertensive patients at high cardiovascular risk. Enrollment for this trial is now complete and this report describes the clinical characteristics of the study cohort. Patients with hypertension and a previous history of cardiovascular events, strokes or diabetes mellitus were randomized to double-blind treatment with either of the two combination regimens. The data in this report detail the clinical history and demographic characteristics in patients immediately prior to randomization to study drugs. A total of 11,454 patients were randomized. Mean age (±SD) was 68.4±6.9 years, 60% were men, and 1360 (12%) were African American. Mean body mass index (BMI) was 31.0±6.3 kg/m2. At study entry, 46% of patients had a history of acute coronary syndromes, coronary artery bypass grafts or percutaneous coronary interventions; 13% had a history of stroke. A history of diabetes mellitus was reported in 6928 (60%) of patients. Mean blood pressure at baseline (on prior hypertension therapy) was 145.4/80.0 Hg; only 38% of patients had a BP less than 140/90mmHg. Overall, 97% of patients had received previous antihypertensive treatment (74% on at least two drugs); 53% were on oral diabetes therapy or insulin, 68% on anti-lipid therapy and 63% on anti-platelet agents. In summary, the ACCOMPLISH trial has recruited hypertensive patients at high risk of cardiovascular morbidity and mortality. It is noteworthy that the mean BMI of 31 in this cohort is clearly above the accepted diagnostic criterion of obesity and that 60% of patients are diabetic, possibly reflecting secular trends in clinical disease.

AB - ACCOMPLISH is the first trial designed to compare the effects on major fatal and non-fatal cardiovascular endpoints of two forms of antihypertensive combination therapy: benazepril plus hydrochlorothiazide and amlodipine plus benazepril in hypertensive patients at high cardiovascular risk. Enrollment for this trial is now complete and this report describes the clinical characteristics of the study cohort. Patients with hypertension and a previous history of cardiovascular events, strokes or diabetes mellitus were randomized to double-blind treatment with either of the two combination regimens. The data in this report detail the clinical history and demographic characteristics in patients immediately prior to randomization to study drugs. A total of 11,454 patients were randomized. Mean age (±SD) was 68.4±6.9 years, 60% were men, and 1360 (12%) were African American. Mean body mass index (BMI) was 31.0±6.3 kg/m2. At study entry, 46% of patients had a history of acute coronary syndromes, coronary artery bypass grafts or percutaneous coronary interventions; 13% had a history of stroke. A history of diabetes mellitus was reported in 6928 (60%) of patients. Mean blood pressure at baseline (on prior hypertension therapy) was 145.4/80.0 Hg; only 38% of patients had a BP less than 140/90mmHg. Overall, 97% of patients had received previous antihypertensive treatment (74% on at least two drugs); 53% were on oral diabetes therapy or insulin, 68% on anti-lipid therapy and 63% on anti-platelet agents. In summary, the ACCOMPLISH trial has recruited hypertensive patients at high risk of cardiovascular morbidity and mortality. It is noteworthy that the mean BMI of 31 in this cohort is clearly above the accepted diagnostic criterion of obesity and that 60% of patients are diabetic, possibly reflecting secular trends in clinical disease.

KW - Cardiovascular outcomes

KW - Clinical trials

KW - Combination therapy

KW - Hypertension

UR - http://www.scopus.com/inward/record.url?scp=34247601068&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247601068&partnerID=8YFLogxK

U2 - 10.1080/08037050701217643

DO - 10.1080/08037050701217643

M3 - Article

C2 - 17453747

AN - SCOPUS:34247601068

VL - 16

SP - 13

EP - 19

JO - Blood Pressure

JF - Blood Pressure

SN - 0803-7051

IS - 1

ER -